Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative QL1706 plus neoadjuvant paclitaxel/cisplatin in resectable locally advanced esophageal squamous cell carcinoma
CTR20250570Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Qilu Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
QL1706
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20250570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250570.